0001104659-23-071772.txt : 20230615
0001104659-23-071772.hdr.sgml : 20230615
20230615210033
ACCESSION NUMBER: 0001104659-23-071772
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230613
FILED AS OF DATE: 20230615
DATE AS OF CHANGE: 20230615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Sushil
CENTRAL INDEX KEY: 0001860609
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 231019169
MAIL ADDRESS:
STREET 1: C/O REPLIMUNE GROUP, INC.
STREET 2: 500 UNICORN PARK, THIRD FLOOR
CITY: WOBURN
STATE: MA
ZIP: 01801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
tm2318878-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-13
0
0001737953
Replimune Group, Inc.
REPL
0001860609
Patel Sushil
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK DRIVE
WOBURN
MA
01801
0
1
0
0
Chief Strategy Officer
1
Common Stock
2023-06-13
4
S
0
5145
24.11
D
149426
D
Common Stock
2023-06-13
4
S
0
553
23.44
D
148873
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.54. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.53. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Following the sales reported on this form 4, the reporting person continues to beneficially own 148,873 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 263,750 shares of the Issuer's common stock, 88,072 of which are exercisable as of the date hereof.
/s/ Shawn Glidden, attorney-in-fact
2023-06-15